A Phase III open-label randomized study to compare the efficacy of lenalidomide–rituximab with bendamustine– rituximab in treatment-naïve follicular lymphoma
Indian Journal of Cancer · 2024
DOI: 10.4103/ijc.ijc_633_20 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Indian Journal of Cancer, 2024. Verfasst von Sushant Kumar Paikaray und 6 weiteren Autor:innen. Beteiligte Einrichtung: All India Institute of Medical Sciences, New Delhi, India. Hauptthemen laut MEDLINE: Lymphoma, Follicular. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 13 Literaturangaben.
Abstract (Originalsprache)
Introduction
Bendamustine–rituximab (BR) is the preferred regimen for the treatment of naïve follicular lymphoma (FL). Recently, lenalidomide–rituximab (LR), a chemotherapy-free protocol, has shown a good response rate in advanced FL. These regimens have never been compared in a randomized controlled trial for treatment-naïve FL in Indian patients. Materials and Methods: This Phase III open-label randomized controlled trial was conducted to compare the efficacy and safety of BR and LR. Treatment-naïve patients older than 18 years of age, ECOG PS (Eastern Cooperative Oncology Group Performance Status) ≤2, who were diagnosed with FL (Stages II–IV) were included in this study. Patients were randomized in a 1:1 ratio to receive six cycles of BR (bendamustine 90 mg/m 2 Days 1–2 and rituximab 375 mg/m 2 Day 1) every 4 weeks or LR (lenalidomide 20 mg Days 1–21 and rituximab 375 mg/m 2 ) every 4 weeks. The primary end point was complete response (CR) and secondary end points were overall response rate (ORR) and toxicity.
Result
We enrolled 40 patients, 20 in each group with a median age of 53 years. The CR rate was 60% and 20% in BR and LR arms, respectively ( P = 0.01); however, the ORR was 88.8% and 87.3% in BR and LR arms, respectively ( P = 1.0). Anemia (35% versus 10%), skin rash (35% versus 30%), diarrhea (30% versus 10%), vomiting (20% versus 10%), nephrotoxicity (15% versus 0%), and transaminitis (10% versus 0%) were more in LR than in BR, and thrombocytopenia was higher in the BR than in the LR group but statistically not different. All grade toxicities were seen in 90% and 45% in LR and BR, respectively ( P = 0.05), but there was no significant difference in Grade 3 or 4 toxicity between the BR and the LR regimens (20% versus 25%).
Conclusion
The ORR was similar in both the arms; however, the CR rate was significantly higher in the BR arm. BR was better tolerated than LR. (CTRI/2016/05/006904).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- All India Institute of Medical Sciences, New Delhi, India.
- Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
- Department of Radiation Oncology, All India Institute of Medical Sciences, AIIMS, New Delhi, India.
- Department of Biostatistics, AIIMS, New Delhi, India.
- Department of Pathology, All India Institute of Medical Sciences, New Delhi, India.
ORCID-Profile: Sushant Kumar Paikaray, Ajay Gogia, Lalit Kumar, Atul Sharma, Ahit Agni Biswas, Sreeniwas Vishnubhatla, Soumya Mallick
Zitieren
APA
Paikaray, S. K., Gogia, A., Kumar, L., Sharma, A., Biswas, A. A., Vishnubhatla, S., & Mallick, S. (2024). A Phase III open-label randomized study to compare the efficacy of lenalidomide–rituximab with bendamustine– rituximab in treatment-naïve follicular lymphoma. Indian Journal of Cancer. https://doi.org/10.4103/ijc.ijc_633_20
Vancouver
Paikaray SK, Gogia A, Kumar L, Sharma A, Biswas AA, Vishnubhatla S, et al. A Phase III open-label randomized study to compare the efficacy of lenalidomide–rituximab with bendamustine– rituximab in treatment-naïve follicular lymphoma. Indian Journal of Cancer. 2024. doi:10.4103/ijc.ijc_633_20
BibTeX
@article{Paikaray2024,
author = {Paikaray, Sushant Kumar and Gogia, Ajay and Kumar, Lalit and Sharma, Atul and Biswas, Ahit Agni and Vishnubhatla, Sreeniwas and Mallick, Soumya},
title = {A Phase III open-label randomized study to compare the efficacy of lenalidomide–rituximab with bendamustine– rituximab in treatment-naïve follicular lymphoma},
journal = {Indian Journal of Cancer},
year = {2024},
doi = {10.4103/ijc.ijc_633_20}
}
EUVIMED